Provided by Tiger Trade Technology Pte. Ltd.

Hoth Therapeutics

0.9930
-0.0170-1.68%
Post-market: 0.9800-0.0130-1.31%19:49 EST
Volume:245.49K
Turnover:243.52K
Market Cap:15.41M
PE:-0.98
High:1.01
Open:0.9900
Low:0.9700
Close:1.01
52wk High:2.12
52wk Low:0.6554
Shares:15.51M
Float Shares:14.96M
Volume Ratio:0.72
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0134
EPS(LYR):-1.2844
ROE:-151.13%
ROA:-84.46%
PB:1.87
PE(LYR):-0.77

Loading ...

BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients

Reuters
·
Jan 22

Hoth Therapeutics Inc - Additional Endpoints Show ~34% Improvement in Oncology Toxicity

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Inc - Ht-001 Well Tolerated With No Unexpected Safety Signals

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction in Disease Severity in Open-Label Pk Cohort of Egfr-Treated Cancer Patients

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Secures Chinese Patent for HT-KIT Cancer Program, Strengthening Global Oncology IP Portfolio

Reuters
·
Jan 21

BRIEF-Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing Ht-001 Oncology Trial Toward Multi-Country Site Activation

Reuters
·
Jan 15

Hoth Therapeutics : Country-Specific Part Ii Regulatory Decisions in Hungary, Spain, & Poland Are Expected by Jan 19, 2026

THOMSON REUTERS
·
Jan 15

Hoth Therapeutics Receives Positive EU Regulatory Conclusion for HT-001 Oncology Trial

Reuters
·
Jan 15

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live
·
Jan 03

Hoth Therapeutics Files Two US Provisional Patents for Oncology-Focused Dermatology Platform; Shares Rise

MT Newswires Live
·
Jan 02

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 05, 2025

Hoth Therapeutics Advances Phase 2 Trial of HT-001 for EGFR-Inhibitor-Associated Rash

Reuters
·
Dec 04, 2025

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated Ht-Kit, Advancing Ht-001 Phase 2, and New Gdnf Metabolic Program

THOMSON REUTERS
·
Dec 04, 2025

Hoth Therapeutics to Present at Noble Capital Markets Emerging Growth Equity Conference

Reuters
·
Dec 01, 2025

Hoth Therapeutics Joins NVIDIA Connect Program to Boost AI-Driven Drug Development

Reuters
·
Nov 20, 2025

Hoth Therapeutics Accepted Into Nvidia Connect Program, Expanding Its AI and Accelerated Computing Capabilities

THOMSON REUTERS
·
Nov 20, 2025

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 17, 2025

Hoth Therapeutics Inc Files for Mixed Shelf Offering of Upto $50 Mln - SEC Filing

THOMSON REUTERS
·
Nov 17, 2025

Hoth Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease

Reuters
·
Oct 27, 2025